kind glp 1 patch GLP-1 Companion System Kind Patches USA: Unmasking the
Description
Treatment with liraglutide injection 1.2 mg and liraglutide injection 1.8 mg resulted in statistically significant reductions in HbA1c relative to sitagliptin 100 mg (Table 5)
Patients with these conditions should discuss their medical history with their healthcare providers before starting GLP-1 therapy
Hawkins, J., Cifuentes, M., Pleshko, N
So, it is a bireceptor agonist, product of the above mentioned peptide engineering, created as a single agent possessing activity at more than one pharmacological target
These side effects may be more pronounced when starting treatment and often decrease over time
